Refractory Acute Myeloid Leukemia (AML)

Refractory Acute Myeloid Leukemia (AML) is the indication for 7 drugs in DrugBank. It is covered by 9 curated, structured indications.

Also known as: Refractory Acute Myeloid Leukemia · Refractory Acute Myelogenous Leukemia · Refractory Acute Myelogenous Leukemia (AML) · Refractory AML · acute, refractory Myeloid Leukemia
Classified under: Hemic and Lymphatic Diseases
Neoplasms
Indicated drugs: Clofarabine
Enasidenib
Gemtuzumab ozogamicin
Ivosidenib
Olutasidenib
Revumenib
Ziftomenib

Resolves to

Vocabularies

SNOMED CT12291000132102MedDRA10081513UMLSC4528668

What you can answer from here — as of November 14, 2026

7Indicated drugsWith each drug's targets and mechanism

Listed above

9Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

203Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Refractory Acute Myeloid Leukemia (AML) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.